Join Us at the Next EAP Webinar
15 May 2025
Children are among the most vulnerable to the often-overlooked harms of alcohol exposure — yet policies and public discourse rarely centre their needs. This timely webinar places children and adolescents at the core of Europe’s alcohol harm reduction efforts.
Building on the themes of the European Alcohol Health Alliance Symposium, the session will explore how children are affected at every stage — from prenatal exposure to the impacts of parental misuse, societal consumption, and pervasive alcohol marketing.
About the Presenters
Technical Officer for Alcohol, Special Initiative on NCDs and Innovation, WHO Regional Office for Europe
EASL Policy, Public Health & Advocacy Committee Member & Chair of Alcohol Action Ireland
Representative of the EAP at the European Alcohol Health Alliance Symposium
Our expert line-up includes Catherine Paradis (WHO Regional Office for Europe), Frank Murray (Alcohol Action Ireland, EASL), and Ann De Guchtenaere (European Academy of Paediatrics), with opening remarks and welcome by the moderator. Together, they will share key evidence, advocacy strategies, and policy actions aimed at reducing alcohol harm across Europe.
Join us for an urgent conversation calling for stronger protections, stricter regulations, and a cultural shift that truly prioritises children’s wellbeing in alcohol policy and prevention.
What You Will Walk Away With
New ways to test high-risk medical devices.
Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.
It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.